)
ICU Medical (ICUI) investor relations material
ICU Medical Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $560.4M, up 4% reported and 5% organically; adjusted EBITDA was $113.9M and adjusted diluted EPS was $2.44.
GAAP net income was $26.8M versus a $3.4M loss a year earlier; stable demand and Consumables and Infusion Systems growth supported results, while distribution disruptions weighed on Vital Care.
Financial highlights
Q3 gross profit was $234.8M versus $200.9M; GAAP gross margin was 41.9% versus 37.4%, supported by pricing, mix and tariff refunds.
Adjusted EBITDA rose to $113.9M from $105.9M; adjusted diluted EPS increased to $2.44 from $2.03.
Q3 free cash flow was $83M; nine-month operating cash flow was $218.6M and free cash flow was $172.7M.
Q3 adjusted SG&A was $114M, adjusted R&D was $21M, and operating expenses were $135M, or 24.3% of revenue.
Outlook and guidance
FY26 adjusted EBITDA guidance is $435M and adjusted diluted EPS guidance is $9.00, the high ends of prior ranges; results are expected toward those levels.
FY26 organic growth outlook: Consumables in the mid-single digits, Infusion Systems at least high-single digits, and Vital Care down mid- to high-single digits.
FY26 CapEx guidance was reduced to $75M from $85M–$100M due to project timing; Q4 CapEx is expected to be materially above the quarterly average to date.
FY gross margin guidance is ~41.5%; the adjusted gross margin target remains 43% exiting 2027, with progress subject to inflation, currency and tariffs.
Q4 free cash flow is expected below Q3; current FX rates imply a neutral currency impact for the rest of 2026.
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Custom and direct-channel growth lifted 2010 results, while Hospira concentration remains a key risk.ICUI
Q4 2010 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020
Next ICU Medical earnings date
Next ICU Medical earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)